Kazia says paxalisib posts 100% clinical benefit rate in six-patient phase 1b metastatic TNBC study

• Kazia reported early Phase 1b data showing all six evaluable patients with advanced triple-negative breast cancer derived clinical benefit on paxalisib.
• Most patients saw tumors shrink, including one complete response that has remained in remission since November 2025.
• Safety looked supportive, with no treatment-related serious adverse events reported in the initial group.
• Enrollment for the ongoing paxalisib combination study is expected to finish by July 2027, with interim updates planned in 2026-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via CNW (Ref. ID: 202608271601CANADANWCANADAPR_C6828) on August 27, 2026, and is solely responsible for the information contained therein.